Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Articles|November 2, 2011
- Pharmaceutical Technology-11-02-2011
- Volume 35
- Issue 11
Pharmaceutical Technology, November 2011 Issue (PDF)
Click the title above to open the Pharmaceutical Technology November 2011 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 15 years ago
Growth for Small Pharmaabout 15 years ago
Drug Shortages Create Crisis for Manufacturers, Regulatorsabout 15 years ago
Using Simulation to Improve Drug-Delivery Effectivenessabout 15 years ago
Easy on the Alcohol!about 15 years ago
Catalyzing the Synthesisabout 15 years ago
Super Fast Pharmaabout 15 years ago
Managing the Global Clinical-Trial Material Supply Chainabout 15 years ago
In the Spotlight November 2011about 15 years ago
Biosimilars' Technology NeedsAdvertisement
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
France Remains One of Europe’s Leading Biotech Funding Hubs
4
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
5